Company news
Jiangsu Jibeier Pharmaceutical Co. Ltd. Class A (SSE:688566) news
Jiangsu Jibeier Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 22, 2026: "Jiangsu Jibeier Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
"Jiangsu Jibeier Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining an Invention Patent
September 21, 2026
"Jiangsu Jibeier Pharmaceutical Co., Ltd."Announcement on Appointment of the Board Secretary
September 14, 2026
"Jiangsu Jibeier Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 9, 2026
"Jiangsu Jibeier Pharmaceutical Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026
August 27, 2026
"Jiangsu Jibeier Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure Regarding the Acquisition of an Invention Patent
July 29, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 17, 2026
Announcement on Voluntary Disclosure of Obtaining Invention Patent Certificate
June 15, 2026
Announcement on Adjusting the Total Profit Distribution in 2025
June 10, 2026
Announcement on Vesting Results and Share Listing in the 1st Vesting Period of Initial Grant in 2025 Restricted Stock Incentive Plan
June 4, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 22, 2026
Announcement on Resolutions of the 22nd Meeting of the 4th Board of Directors
May 20, 2026
Report for Q1 2026
April 27, 2026
Announcement on Adjusting Grant Price of Restricted Stocks in 2025 Restricted Stock Incentive Plan
April 10, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Completion of Certain IPO Fundraising Projects with Permanent Replenishment of Remaining Funds and Adjustment of Implementation Progress for Certain IPO Fundraising Projects
December 29, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 7, 2025
Report for Q3 2025
October 30, 2025
Announcement on Receiving Approval for Marketing of Chemical APIs
October 23, 2025
Announcement on Resignation of Director and Election of Employee Representative Director
October 22, 2025
Announcement on Progress in Arbitration
October 14, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
October 9, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 26, 2025
Announcement on Progress in Litigation
September 16, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 9, 2025
Announcement on Using Temporarily Idle Raised Funds for Cash Management
August 29, 2025
Announcement on Voluntary Disclosure Regarding the Approval Notice for Drug Clinical Trials of the Investigational Anti-Tumor Drug JJH201601 Liposome for Injection
July 10, 2025
Announcement on Receipt of the Award and Progress in Arbitration Matter
June 20, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 5, 2025
Announcement on Results of Share Reduction by Shareholder with Over 5% Shares and Director
May 29, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 28, 2025
Indicative Announcement on Change in Equity of Shareholder with Over 5% Shares and Director and Person Acting in Concert Reaching 1% Scale
May 26, 2025
Announcement on Receiving Notice from the Court
April 25, 2025
Announcement on Resolutions of the 16th Meeting of the 4th Board of Directors
April 23, 2025
Announcement on Attending the Annual Collective Performance Briefing for Chemical Drug Industry on STAR Market 2024
April 16, 2025
Special Report on 2024 Annual Deposit and Actual Use of Raised Funds
April 14, 2025
Board of Supervisors' Review and Publicity Status Explanation on the List of Initial Grant Incentive Objects for the 2025 Restricted Stock Incentive Plan
April 7, 2025
Announcement on Results of Share Reduction by Shareholders with Over 5% Shares
April 3, 2025
Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 1%
April 2, 2025
Announcement on Resolution of the 13th Meeting of the 4th Board of Supervisors
March 28, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Shareholding Reduction Plan for Shareholders and Directors with Over 5% Shares
February 6, 2025
Announcement on Voluntary Disclosure of Receiving Drug Registration Certificate
January 22, 2025
Announcement on Adjusting Implementation Schedule of Some Investment Projects Financed by Funds Raised from Initial Public Offering of Shares
December 27, 2024
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
December 19, 2024
Announcement on the Listing and Circulation of Restricted Shares Issued to Specific Objects with Summary Procedure
December 13, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 18, 2024
Announcement on Implementation of Dividend Distribution for Q1-Q3 2024
November 7, 2024
Report for Q3 2024
October 30, 2024
Announcement on Price Adjustment for the Restricted Stocks under the 2020 and 2022 Restricted Stock Incentive Plan
October 25, 2024
Announcement on Changing Registered Capital and Amending Articles of Association
September 24, 2024